Article

DynamicARC, the next revolution in proton therapy

In the ever-evolving landscape of cancer treatment, can the future of cancer care be shaped by proton arc therapy with DynamicARC®*?  ​

DynamicARC

The evolution of arc therapy with protons

Over the past decades, significant advances have been made in radiotherapy and proton therapy, including progress in treatment planning systems, quality of beam delivery, improved dose distributions and conformity, and improved target volume definition and delineation accuracy.​

​One of the most recent advances is the development of arc therapy, in which radiation is delivered by continuously rotating the radiation source. This allows the cancer patient to be treated with continuous beam delivery as the gantry rotates.​

​In proton therapy, the use of arc therapy with protons was suggested for the first time in 1997.1 The first in-silico study showing the potential of proton arc therapy to improve dose conformity was published in 2013.2 Then, in 2016, Ding et al. described the first proton spot-scanning arc optimization method compatible with existing proton therapy systems, using a ProteusONE system.3 Two years later, in 2018, IBA in partnership with Corewell Health (formerly William Beaumont Hospital) successfully performed the first prototype of dynamic proton arc delivery on a Proteus proton therapy system.4​

​IBA and its clinical, industrial and research partners aim to revolutionize cancer care by developing the first spot-scanning proton arc method, DynamicARC, using the ProteusONE system. 

DynamicARC brochure preview

Discover the complete history of Arc Therapy by downloading the DynamicARC® Solution Paper:

Download access

Please fill in the form to download the document.

First name*
Last name*
Professional Email*
Job title*
Country*
Company*
Best
describes me*
IBA uses and stores cookies and other tracking technologies as specified in the IBA's Cookies Policy to improve your browsing experience on our website, and to understand where our visitors are coming from.

Your information will be collected, stored, and used according to IBA’s Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PONE

The promise of DynamicARC

DynamicARC is expected to potentially be a novel and innovative treatment approach  allowing simultaneous dynamic beam delivery at variable energies while the gantry is rotating. ​

​Intensity Modulated Proton Therapy (IMPT) is now the current clinical practice where treatment is delivered in 2-3 static fields; however, DynamicARC helps target the tumor from an increased number of directions, enhancing tumor coverage and healthy tissue sparing.​

​IBA is committed to making proton therapy accessible to all patients who could benefit from it, and DynamicARC is an important step on this journey.

Delivering sharper, faster and simpler treatment

DynamicARC has the potential to significantly improve treatment delivery, allowing sharper, faster and simpler treatment.​

  • ​Sharper​

DynamicARC could make treatment sharper by delivering an expected ​

lower integral dose and offering better dose conformity. This new modality may increase by 22% the number of patients eligible for proton therapy.5,6​

  • ​Faster​

With an optimized workflow, DynamicARC can be faster than IMPT, allowing for higher patient throughput. Reductions of 58% of the average treatment delivery time per patient were estimated, and up to 30% increase in patient throughput compared to IMPT.7 ​

  • Simpler​

DynamicARC is simpler than IMPT, avoiding complex beam arrangements, with fewer therapist actions such as couch rotations or accessory insertions between fields, simplifying treatment planning and delivery.​

ArcBrochurePicture.jpg

Discover the promise and advantages of DynamicARC by downloading the DynamicARC® Solution Paper:

First name*
Last name*
Professional Email*
Job title*
Country*
Company*
Best
describes me*
IBA uses and stores cookies and other tracking technologies as specified in the IBA's Cookies Policy to improve your browsing experience on our website, and to understand where our visitors are coming from.

Your information will be collected, stored, and used according to IBA’s Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PONE

Clinical indications for DynamicARC​

DynamicARC is expected to benefit a wide range of clinical indications.

Over 150 patient cases** across 10 clinical studies have already compared plans with DynamicARC on ProteusONE with other treatment modalities. DynamicARC has shown encouraging results in brain cancer, head and neck cancer, breast cancer, lung cancer, prostate cancer and spine metastases, among others.

Among them, DynamicARC has shown the potential to significantly reduce the dose delivered to organs at risk across several indications. It also greatly simplifies workflow, may reduces toxicities, further improves the target coverage conformity and robustness, adds flexibility to achieve a more favorable linear energy transfer distribution with high LET inside the target, and better adapts to patient conditions and clinical resources available.8-15

DynamicARC may benefit a wide range of cancer types​​

Download the DynamicARC® Solution Paper and discover the published results of using DynamicARC across indications:​

Download the DynamicARC® Solution Paper and discover the published results of using DynamicARC across indications:

First name*
Last name*
Professional Email*
Job title*
Country*
Company*
Best
describes me*
IBA uses and stores cookies and other tracking technologies as specified in the IBA's Cookies Policy to improve your browsing experience on our website, and to understand where our visitors are coming from.

Your information will be collected, stored, and used according to IBA’s Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Notes​

* DynamicARC is the registered brand of IBA’s Proton Arc therapy solution which is currently under research and development. DynamicARC will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.​
** As of September 2023​

​References​

  1. Deasy JO et al. “Comformal Proton Tomotherapy Using Distaledge Tracking.” Radiotherapy and Oncology 37 (1995): S43.​
  2. Seco J et al. “Proton Arc Reduces Range Uncertainty Effects and Improves Conformality Compared with Photon Volumetric Modulated Arc Therapy in Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer.” International Journal of Radiation Oncology Biology Physics 87, no. 1 (2013): 188–94.​
  3. Ding X et al. “Spot-Scanning Proton Arc (SPArc) Therapy – The First Robust and Delivery-Efficient Spot-Scanning Arc Therapy.” International Journal of Radiation Oncology • Biology • Physics 0, no. 0 (2016): 1107–16.​
  4. Li X et al. “The First Prototype of Spot-Scanning Proton Arc Treatment Delivery.” Radiotherapy and Oncology 137 (2019): 130–36.​
  5. de Jong B et al. Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model-based clinic. Radiother Oncol. 2023:184;109670. ​
  6. de Jong B et al. Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. Med Phys. 2023;50(3):1305-1317.​
  7. Liu G et al. Development of a standalone delivery sequence model for proton arc therapy. Med Phys. 2023. doi: 10.1002/mp.16879. ​
  8. Ding X et al. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol. 2019;58(4):483-490.​
  9. Chang S et al. Redefine the Role of Spot-Scanning Proton Beam Therapy for the Single Brain Metastasis Stereotactic Radiosurgery. Front Oncol. 2022;12:804036.​
  10. Chang S et al. Feasibility study: spot-scanning proton arc therapy (SPArc) for left-sided whole breast radiotherapy. Radiat Oncol. 2020;15:232.​
  11. Liu G et al. Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study. Radiat Oncol. 2020;15(1):21.​
  12. Ding X et al. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018;57(3):435-437. ​
  13. Liu G et al. Is proton beam therapy ready for single fraction spine SBRS? - a feasibility study to use spot-scanning proton arc (SPArc) therapy to improve the robustness and dosimetric plan quality. Acta Oncol. 2021;60(5):653-657.​
  14. Li X et al. Linear Energy Transfer Incorporated Spot-Scanning Proton Arc Therapy Optimization: A Feasibility Study. Front Oncol. 2021;11:698537.​
  15. Wuyckens S et al. Bi-criteria Pareto optimization to balance irradiation time and dosimetric objectives in proton arc therapy. Phys Med Biol. 2022;67(24).​
MID127275

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Cookies policies